BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2026 3:41:42 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-08-07 01:48 |
|
Peer-Review Started |
|
2025-08-07 01:49 |
|
First Decision by Editorial Office Director |
|
2025-08-20 07:57 |
|
Return for Revision |
|
2025-08-20 07:57 |
|
Revised |
|
2025-09-01 17:58 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-24 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-24 10:17 |
|
Articles in Press |
|
2025-11-24 10:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-04 00:11 |
|
Publish the Manuscript Online |
|
2026-02-11 03:41 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sayan Malakar, Suprabhat Giri, Anuraag Jena and Preetam Nath |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Suprabhat Giri, Associate Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Road, Patia, Bhubaneswar 751024, Odisha, India. supg19167@gmail.com |
| Key Words |
Janus kinase inhibitors; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease |
| Core Tip |
Janus Kinase inhibitors are reserved for moderate-to-severe inflammatory bowel disease (IBD) after biologic failure or steroid dependence. Carefully selecting patients based on their cardiovascular, thromboembolic, and infection-related risks is of paramount importance. Tofacitinib is an excellent choice for patients with moderate to severe ulcerative colitis (UC) and acute severe UC. Upadacitinib is currently approved for both refractory UC and Crohn’s disease (CD); however, emerging data suggest its beneficial role in acute severe UC. Limited evidence exists for the combination of small molecules and other biologicals in patients with difficult-to-treat IBD and peri-anal CD. Close monitoring of side effects is advocated in such patients. More data is warranted on their role in extraintestinal manifestations, IBD in pediatric and pregnant patients with IBD. |
| Publish Date |
2026-02-11 03:41 |
| Citation |
Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788 |
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i1/112788.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v17.i1.112788 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
